PDE5 inhibitors beyond erectile dysfunction

  title={PDE5 inhibitors beyond erectile dysfunction},
  author={Peter Sandner and Joachim Huetter and Hanna Tinel and Kathrin Ziegelbauer and Erwin Bischoff},
  journal={International Journal of Impotence Research},
The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil in 1998, more than 40 million men worldwide have been successfully treated with these compounds. The safety and high tolerability of PDE5 inhibitors make them an attractive tool to investigate further physiological functions of PDE5, for example the modulation of intracellular cyclic GMP (cGMP) pools. As cGMP is a… CONTINUE READING